Biopolymers · 2002 · 106 citations · 25 references
MedicineOncologyPharmacologyEndocrine OncologyMolecular ImagingRadionuclide TherapyEndocrine Tumor ImagingNeuroendocrine Tumor TherapyNeuroendocrine TumorsPeptide Receptor Radionuclide TherapySomatostatin Receptor ImagingTumor Receptor ImagingConcentrationHydrophilicityPeptide Receptor Radionuclide Therapy ImagingSomatostatin Analog TherapySomatostatin AnaloguesSomatostatin PharmacologySomatostatin Receptor ScintigraphySomatostatin Receptor Therapy
Somatostatin receptors type 2 (sst(2)) are expressed in high concentration on numerous neudoendocrine tumors. The successful use of radiolabeled somatostatin analogs in imaging promoted further studies in utilizing them in radiopeptide therapy. The somatostatin analog [(90)Y-DOTA-D-Phe(1)-Try3]octreotide (DOTATOC) (DOTA: 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid) possesses favorable characteristic for its therapeutic use; shows high affinity for sst(2), moderately high affinity for sst(5), and intermediate affinity for sst(3); high hydrophilicity; stable and facile labeling with (111) In and (90) Y. In this article we report our experience with (90)Y-DOTATOC in neuroendocrine tumors. Eighty-seven patients with neuroendocrine tumors were treated with a cumulated activity ranging from 7.4 to 20.2 GBq. Most patients responded with stabilization of disease (48%); however, objective responses were observed in 28% of patients (5% complete response). No major acute reactions were observed up to the activity of 5.55 GBq per cycle. The dose limiting was bone marrow toxicity and the maximal tolerated dose was defined as 5.18 GBq.
25
Reporting results of cancer treatment
A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
W. Bauer, U. Briner, W. Doepfner et al. · Life Sciences · 1982 · 1.3K citations
Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 1.1K citations
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Christian Waldherr, Miklos Pless, Helmut R. Maëcke et al. · PubMed · 2002 · 446 citations
Medicine, Oncology, Pharmacology +15